Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Thoracic 4Plasma cell 1Gynecologic 1

Conditions

Multiple Myeloma 873Neoplasms, Plasma Cell 162Lymphoma, Non-Hodgkin 139Lymphoma 135Hodgkin Disease 134Leukemia, Lymphocytic, Chronic, B-Cell 118Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Myelodysplastic Syndromes 103Recurrence 101Leukemia, Myeloid, Acute 99Leukemia 94Lymphoma, Mantle-Cell 80Lymphoma, Large B-Cell, Diffuse 76Lymphoma, Follicular 73Myeloproliferative Disorders 69Lymphoma, B-Cell, Marginal Zone 69Hematologic Neoplasms 64Burkitt Lymphoma 64Primary Myelofibrosis 57Lymphoma, Large-Cell, Immunoblastic 55Waldenstrom Macroglobulinemia 52Leukemia, Myelogenous, Chronic, BCR-ABL Positive 52Leukemia, Myeloid, Chronic-Phase 46Lymphoma, T-Cell, Cutaneous 44Immunoglobulin Light-chain Amyloidosis 43Congenital Abnormalities 43Neoplasms 41Leukemia, Myelomonocytic, Chronic 41Leukemia, Myeloid, Accelerated Phase 40Sezary Syndrome 38

Interventions

carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Kidney Failure, Chronic × Plasma cell × Clear all
NCT01949532 2017-05-02

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

Amgen

Phase 1 Completed
26 enrolled 41 charts
GenitourinaryPlasma cell

Kidney Failure, Chronic, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡